Last reviewed · How we verify

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine

University of Wisconsin, Madison · FDA-approved active Small molecule

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine is a Multimodal analgesic combination Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved for Acute and chronic pain management, Postoperative pain.

This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways.

This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways. Used for Acute and chronic pain management, Postoperative pain.

At a glance

Generic namemultimodal:acetaminophen, gabapentin, ketamine, bupivacaine
SponsorUniversity of Wisconsin, Madison
Drug classMultimodal analgesic combination
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Acetaminophen inhibits prostaglandin synthesis; gabapentin modulates calcium channels and reduces neuronal excitability; ketamine antagonizes NMDA receptors to block pain signaling; and bupivacaine is a local anesthetic that blocks sodium channels. Together, these agents target pain through peripheral, spinal, and central mechanisms, allowing lower individual doses and potentially reducing adverse effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about multimodal:acetaminophen, gabapentin, ketamine, bupivacaine

What is multimodal:acetaminophen, gabapentin, ketamine, bupivacaine?

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine is a Multimodal analgesic combination drug developed by University of Wisconsin, Madison, indicated for Acute and chronic pain management, Postoperative pain.

How does multimodal:acetaminophen, gabapentin, ketamine, bupivacaine work?

This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways.

What is multimodal:acetaminophen, gabapentin, ketamine, bupivacaine used for?

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine is indicated for Acute and chronic pain management, Postoperative pain.

Who makes multimodal:acetaminophen, gabapentin, ketamine, bupivacaine?

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine is developed and marketed by University of Wisconsin, Madison (see full University of Wisconsin, Madison pipeline at /company/university-of-wisconsin-madison).

What drug class is multimodal:acetaminophen, gabapentin, ketamine, bupivacaine in?

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine belongs to the Multimodal analgesic combination class. See all Multimodal analgesic combination drugs at /class/multimodal-analgesic-combination.

What development phase is multimodal:acetaminophen, gabapentin, ketamine, bupivacaine in?

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine is FDA-approved (marketed).

What are the side effects of multimodal:acetaminophen, gabapentin, ketamine, bupivacaine?

Common side effects of multimodal:acetaminophen, gabapentin, ketamine, bupivacaine include Dizziness, Sedation, Nausea, Local injection site reactions.

Related